| Abstrakt: |
Researchers at Tianjin Cancer Hospital in China have published a case report on a patient with non-small cell lung cancer (NSCLC) who developed resistance to osimertinib, a targeted therapy. The patient received erlotinib as a second-line treatment, followed by osimertinib, which showed clinical activity for 19 months before the emergence of an EML4-ALK fusion. The patient then received ensartinib as a third-line treatment, which resulted in a durable response for over 14 months. This case highlights the potential of ensartinib as a promising treatment option for NSCLC patients with acquired EML4-ALK fusion after osimertinib resistance. [Extracted from the article] |
